… mg dose of the monoclonal antibody combination casirivimab and imdevimab (CAS + IMD)
… 2-infected individuals over a 1-month efficacy assessment period. Here we present additional …

… The selection of safe and effective therapeutic agents is of paramount importance. This …
aims to evaluate the efficacy and safety of the combination of casirivimab and imdevimab in the …

… This study compared casirivimab and imdevimab with remdesivir and favipravir for use in
COVID-19 hospitalized patients. There is no similar treatment comparison or related studies to …

Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-COV
® ) reduced viral load, hospitalisation, or death when administered 1:1 as an intravenous (…

… mg and greater IV efficacy results noted previously, assessed the virologic efficacy and safety
of lower doses of IV and subcutaneous (SC) casirivimab and imdevimab in outpatients with …

… Hereafter, doses of casirivimab plus imdevimab refer to the sum dose of the … to casirivimab
600 mg plus imdevimab 600 mg) and casirivimab plus imdevimab is referred to as casirivimab/…

Aim: of Study: To compare the efficacy and safety of casirivimab and imdevimab, Remdesivir
and Favipravir as antiviral agents in hospitalized COVID19 patients. Patients and Population…

… This randomized, double-blind, placebo-controlled, phase 3 trial assessed the efficacy of
casirivimab and imdevimab in preventing progression to symptomatic SARS-CoV-2 infection …

… , and the Delta variant became dominant in the US in summer 2021, we evaluated the
effectiveness of casirivimab-imdevimab and sotrovimab from July 2021 to September 2021. …

… the clinical efficacy of casirivimab-imdevimab in patients with … The clinical efficacy of
casirivimab-imdevimab combination … the clinical efficacy of casirivimab-imdevimab in patients with …